Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Fabrication of a vascularized bioartificial pancreas using macroencapsulation of stem cell-derived pancreatic islet cells for the treatment of type 1 Diabetes.

FY 2020-21

Summary
Type 1 diabetes affects more than 300 000 Canadians and its impact continues to rise in Canada and the world. Transplantation of pancreatic islets, the tissue regulating insulin and blood sugar, is a promising strategy to treat diabetic patients because it can eliminate their dependence on external insulin sources for many months. There are however severe disadvantages with this approach. One of the most critical problem is graft rejection, a process where your own immune system attacks the newly transplanted tissue and destroys it. To protect the islets, scientists are encapsulating them in selectively permeable materials. These are biocompatible materials that create a physical barrier to prevent the immune cells to reach the graft while allowing nutrients to go through to keep the islets alive. Unfortunately, the large quantity of islets needed to treat human diabetic patients make it difficult to have enough nutrients for all the graft, leading to significant cell death and failure of the therapy. To address these issues, we are fabricating a small device that can encapsulate several hundred thousand islets and protect them from immune destruction. To optimize survival of the graft, our device contains many blood vessel-like channels that can be directly irrigated by the patient's own blood after transplantation. With our approach, the islets inside the device will take on the function of the patient's failing pancreas, producing the insulin needed to regulate blood sugar level for several years. This strategy will allow patients suffering from type 1 diabetes to be treated by islet transplant without suffering from the difficult complications related to immunosuppression or insulin management. It thus represents an important advance in cellular therapy for diabetic patients.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
437123
Name
Brassard Jonathan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Fabrication of a vascularized bioartificial pancreas using macroencapsulation of stem cell-derived pancreatic islet cells for the treatment of type 1 Diabetes.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Biomaterials; Biomedical Device; Diabetes; Pancreatic Islets; Stem Cells; Transplantation
Abstract
Type 1 diabetes affects more than 300 000 Canadians and its impact continues to rise in Canada and the world. Transplantation of pancreatic islets, the tissue regulating insulin and blood sugar, is a promising strategy to treat diabetic patients because it can eliminate their dependence on external insulin sources for many months. There are however severe disadvantages with this approach. One of the most critical problem is graft rejection, a process where your own immune system attacks the newly transplanted tissue and destroys it. To protect the islets, scientists are encapsulating them in selectively permeable materials. These are biocompatible materials that create a physical barrier to prevent the immune cells to reach the graft while allowing nutrients to go through to keep the islets alive. Unfortunately, the large quantity of islets needed to treat human diabetic patients make it difficult to have enough nutrients for all the graft, leading to significant cell death and failure of the therapy. To address these issues, we are fabricating a small device that can encapsulate several hundred thousand islets and protect them from immune destruction. To optimize survival of the graft, our device contains many blood vessel-like channels that can be directly irrigated by the patient's own blood after transplantation. With our approach, the islets inside the device will take on the function of the patient's failing pancreas, producing the insulin needed to regulate blood sugar level for several years. This strategy will allow patients suffering from type 1 diabetes to be treated by islet transplant without suffering from the difficult complications related to immunosuppression or insulin management. It thus represents an important advance in cellular therapy for diabetic patients.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Brassard, Jonathan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McGill University - $150,000 Grant (2020-21) | Canada Spends